OTCM
CLVLY
Market cap365mUSD
Jul 09, Last price
7.16USD
1D
3.32%
1Q
13.65%
Jan 2017
35.35%
IPO
-3.89%
Name
Clinuvel Pharmaceuticals Ltd
Chart & Performance
P/E
14.37
P/S
5.47
EPS
0.72
Div Yield, %
0.49%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
23.88%
Revenues
95m
+7.76%
Net income
36m
+1.50%
CFO
41m
+10.91%
Dividend
Sep 09, 20240.034 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||